A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-β1a using RebiSmart™—the FUTURE study-Reference-Cited by-同舟云学术

A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-β1a using RebiSmart™—the FUTURE study

Published:2017-08-22 Issue:11 Volume:38 Page:1999-2005
ISSN:1590-1874
Container-title:Neurological Sciences
language:en
Short-container-title:Neurol Sci

Author:

Ghezzi A.^ORCID, ,Bianchi A.,Baroncini D.,Bertolotto A.,Malucchi S.,Bresciamorra V.,Lanzillo R.,Milani N.,Martinelli V.,Patti F.,Chisari C.,Rottoli M.,Simone M.,Paolicelli D.,Visconti A.

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health,Neurology (clinical),Dermatology,General Medicine

Link

http://link.springer.com/article/10.1007/s10072-017-3091-6/fulltext.html

Reference38 articles.

1. Bar-Or A (2016) Multiple sclerosis and related disorders: evolving pathophysiologic insights. Lancet Neurol 15:9–11

2. Banwell B, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M (2007) Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol 6:887–902

3. Belman AL, Krupp LB, Olsen CS, Rose JW, Aaen G, Benson L (2016) Characteristics of children and adolescents with multiple sclerosis. Pediatrics 138:pii:e20160120

4. Mah JK, Thannhauser JE (2010) Management of multiple sclerosis in adolescents—current treatment options and related adherence issues. Adolesc Health Med Ther 1:31–43

5. Ghezzi A (2010) Therapeutic strategies in childhood multiple sclerosis. Ther Adv Neurol Disord 3:217–228

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. REBISTART: Adherence of Patients with Multiple Sclerosis to Treatment with Subcutaneous Interferon Beta in the Context of a Patient Support Program;Neurology and Therapy;2024-03-26

2. Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives;Neurology and Therapy;2024-01-11

3. Neuropsychological performances, quality of life, and psychological issues in pediatric onset multiple sclerosis: a narrative review;Neurological Sciences;2023-12-29

4. Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation;Expert Review of Clinical Immunology;2023-09-11

5. Chronisch entzündliche ZNS-Erkrankungen;Transition bei neurologischen Erkrankungen;2023